Baseline characteristics according to total incident CVD at end of follow-up
| . | No incident CVD . | Total incident CVD . | Total SMART subset . |
|---|---|---|---|
| n | 716 | 287 | 1,003 |
| Age (years) | 57.4 ± 10.5 | 63.3 ± 9.3 | 59.1 ± 10.5 |
| Sex (male) | 66.1 | 77.4 | 69.3 |
| HbA1c (%) | 7.4 ± 1.4 | 7.4 ± 1.4 | 7.4 ± 1.4 |
| HbA1c (mmol/mol) | 57.0 ± 15.0 | 57.0 ± 15.0 | 57.0 ± 15.0 |
| Glucose-lowering treatment | 94.2 | 95.5 | 94.5 |
| BMI (kg/m2) | 29.1 ± 5.2 | 28.1 ± 4.3 | 28.8 ± 5.0 |
| Total cholesterol (mmol/L) | 5.2 ± 1.5 | 5.2 ± 1.1 | 5.2 ± 1.4 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.4 | 1.1 ± 0.3 | 1.1 ± 0.3 |
| LDL cholesterol (mmol/L) | 3.0 ± 1.1 | 3.2 ± 0.9 | 3.0 ± 1.0 |
| Triglycerides (mmol/L) | 1.9 (1.3–2.8) | 1.9 (1.3–2.6) | 1.9 (1.3–2.7) |
| Lipid-modifying treatment | 45.5 | 48.9 | 45.9 |
| Serum creatinine (µmol/L) | 86.3 ± 26.3 | 108.7 ± 85.6 | 92.7 ± 51.8 |
| eGFR (mL/min/1.73 m2) | 82.4 ± 21.5 | 72.5 ± 23.1 | 79.5 ± 22.4 |
| Albuminuria (normo/micro/macro) | 76.0/20.9/3.1 | 67.6/23.7/8.7 | 73.6/21.7/4.7 |
| Systolic blood pressure (mmHg) | 145.5 ± 20.2 | 149.3 ± 23.7 | 146.6 ± 21.3 |
| Diastolic blood pressure (mmHg) | 83.8 ± 11.0 | 81.1 ± 12.2 | 83.0 ± 11.4 |
| Antihypertensive treatment | 55.7 | 53.0 | 54.9 |
| Smoking (yes) | 26.7 | 33.0 | 28.7 |
| CRP (mg/L) | 2.5 (1.3–5.2) | 3.7 (1.5–7.8) | 2.8 (1.3–6.0) |
| MGO (nmol/L) | 312.7 (279.5–362.5) | 328.2 (286.2–391.5) | 317.0 (282.1–368.2) |
| GO (nmol/L) | 735.1 (585.8–883.2) | 725.8 (587.4–923.5) | 731.4 (586.7–890.8) |
| 3-DG (nmol/L) | 1,369.6 (1,139.1–1,716.3) | 1,399.2 (1,140.7–1,839.6) | 1,376.6 (1,140.7–1,748.7) |
| Prior CVD | 56.8 | 81.1 | 61.6 |
| . | No incident CVD . | Total incident CVD . | Total SMART subset . |
|---|---|---|---|
| n | 716 | 287 | 1,003 |
| Age (years) | 57.4 ± 10.5 | 63.3 ± 9.3 | 59.1 ± 10.5 |
| Sex (male) | 66.1 | 77.4 | 69.3 |
| HbA1c (%) | 7.4 ± 1.4 | 7.4 ± 1.4 | 7.4 ± 1.4 |
| HbA1c (mmol/mol) | 57.0 ± 15.0 | 57.0 ± 15.0 | 57.0 ± 15.0 |
| Glucose-lowering treatment | 94.2 | 95.5 | 94.5 |
| BMI (kg/m2) | 29.1 ± 5.2 | 28.1 ± 4.3 | 28.8 ± 5.0 |
| Total cholesterol (mmol/L) | 5.2 ± 1.5 | 5.2 ± 1.1 | 5.2 ± 1.4 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.4 | 1.1 ± 0.3 | 1.1 ± 0.3 |
| LDL cholesterol (mmol/L) | 3.0 ± 1.1 | 3.2 ± 0.9 | 3.0 ± 1.0 |
| Triglycerides (mmol/L) | 1.9 (1.3–2.8) | 1.9 (1.3–2.6) | 1.9 (1.3–2.7) |
| Lipid-modifying treatment | 45.5 | 48.9 | 45.9 |
| Serum creatinine (µmol/L) | 86.3 ± 26.3 | 108.7 ± 85.6 | 92.7 ± 51.8 |
| eGFR (mL/min/1.73 m2) | 82.4 ± 21.5 | 72.5 ± 23.1 | 79.5 ± 22.4 |
| Albuminuria (normo/micro/macro) | 76.0/20.9/3.1 | 67.6/23.7/8.7 | 73.6/21.7/4.7 |
| Systolic blood pressure (mmHg) | 145.5 ± 20.2 | 149.3 ± 23.7 | 146.6 ± 21.3 |
| Diastolic blood pressure (mmHg) | 83.8 ± 11.0 | 81.1 ± 12.2 | 83.0 ± 11.4 |
| Antihypertensive treatment | 55.7 | 53.0 | 54.9 |
| Smoking (yes) | 26.7 | 33.0 | 28.7 |
| CRP (mg/L) | 2.5 (1.3–5.2) | 3.7 (1.5–7.8) | 2.8 (1.3–6.0) |
| MGO (nmol/L) | 312.7 (279.5–362.5) | 328.2 (286.2–391.5) | 317.0 (282.1–368.2) |
| GO (nmol/L) | 735.1 (585.8–883.2) | 725.8 (587.4–923.5) | 731.4 (586.7–890.8) |
| 3-DG (nmol/L) | 1,369.6 (1,139.1–1,716.3) | 1,399.2 (1,140.7–1,839.6) | 1,376.6 (1,140.7–1,748.7) |
| Prior CVD | 56.8 | 81.1 | 61.6 |
Data are presented as means ± SD, median (interquartile range), or percentage, as appropriate, unless otherwise indicated. normo/micro/macro, normoalbuminuria/microalbuminuria/macroalbuminuria.